Advertisement

Topics

Debiopharm Acquires Wee-1 Kinase Inhibitor Program from Almac Discovery

05:05 EDT 21 Jun 2017 | Genetic Engineering News

Swiss biopharma Debiopharm International negotiated global rights to Almac Discovery’s Wee-1 kinase inhibitor program. The deal gives Debiopharm exclusive rights to Almac Discovery’s Wee-1 patent portfolio and associated IP, in return for an undisclosed upfront payment, plus future development and commercial milestone payments, and sales royalties. Almac Discovery has developed and optimized a series of oral, selective inhibitors of Wee-1 kinase, a regulator of the G2 checkpoint. Commenting on the deal, Dr. Bertrand Ducrey, CEO of Swiss specialty pharma Debiopharm, said, “Almac Discovery’s compelling expertise in medicinal chemistry and drug discovery is very complementary with Debiopharm business model and we look forward to developing these compounds to offer an innovative treatment for patients with high medical need.” Last month, Debiopharm acquired ImmunoGen’s anti-CD37 antibody-drug conjugate IMGN529 (Debio 1562) ,  which is poised to start in Phase II evaluation against non-Hodgkin lymphomas, including diffuse large-cell B-cell lymphoma ...

Original Article: Debiopharm Acquires Wee-1 Kinase Inhibitor Program from Almac Discovery

NEXT ARTICLE

More From BioPortfolio on "Debiopharm Acquires Wee-1 Kinase Inhibitor Program from Almac Discovery"

Advertisement
Quick Search
Advertisement
Advertisement